View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 2, 2021updated 20 Jul 2022 1:11pm

Singapore grants approval to Cue Health’s Covid-19 test for self-use

Cue Health has partnered with Omnicell to begin the immediate supply of its Covid-19 test in Singapore.

The Health Sciences Authority (HSA) in Singapore has authorised the use of Cue Health ’s molecular Covid-19 test for self-testing.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The Cue Covid-19 test for self-testing was approved by the HSA through its Pandemic Special Access Route (PSAR).

With the authorisation, the test can now be used at home to detect infection in both symptomatic and asymptomatic individuals above two years of age.

Cue Health has already partnered with local company Omnicell to begin immediately supplying the Cue Covid-19 Test in Singapore.

Omnicell regional account director Yoco Ting said: “Testing remains an important component in Singapore’s overall strategy for managing Covid-19.

“With the recent authorisation of the Cue Covid-19 Test via the PSAR, Omnicell is excited to bring forth into Singapore the technological advancement from Cue and further simplify the Covid-19 testing process by now combining the speed of rapid antigen tests with the lab-quality accuracy of PCR tests.

“We will continue to work closely with local authorities and Cue to further the effort in controlling Covid-19 in Singapore.”

Cue Health is a healthcare technology company headquartered in San Diego, California, US.

Last month, the company introduced its direct-to-consumer (DTC) virtual health platform in the US. The move made its molecular Covid-19 test available through the company’s new eCommerce site and in-app shop.

Commenting on the approval in Singapore, Cue co-founder and CEO Ayub Khattak said: “We are excited to bring Cue’s digitally connected, in-home molecular diagnostics platform to Singaporean stakeholders and help provide immediate access to critical health information.

“With Cue, users will be able to make faster and more informed healthcare decisions at a time when it’s needed most.”

In February, Cue received CE mark for its molecular point-of-care Covid-19 test in the European Union (EU).

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network